Square Pharmaceuticals PLC, country's leading drug maker, has decided to invest Tk650 crore for business expansion to strengthen its footprint in the pharma market.

The company took the decision at a board meeting held on Wednesday.

According to the company's price sensitive statement, the board of Square Pharma also recommended a record 120% cash dividend for FY25.

To approve the dividend, the company has scheduled the annual general meeting date for 15 December, and the record date for 16 November.

During the last fiscal year, its consolidated net profit was Tk2,397 crore and earnings per share was Tk27.04, which was 15% higher from the previous year.

 

Square Pharma